EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment

Rossella Cicchetti, Martina Basconi, Giulio Litterio iD, Angelo Orsini iD, Marco Mascitti, Alessio Digiacomo iD, Gaetano Salzano, Octavian Sabin Tătaru iD, Matteo Ferro, Carlo Giulioni iD, Angelo Cafarelli, Luigi Schips und 1 weitere

International Journal of Molecular Sciences · 02.12.2025 · 26 (23) · 11665

DOI: 10.3390/ijms262311665 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.12.2025. Verfasst von Rossella Cicchetti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oral and Biotechnological Science, Università degli Studi "G. d'Annunzio" of Chieti, 66100 Chieti, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) remains one of the most prevalent malignancies among men worldwide and continues to pose significant therapeutic challenges, especially in its metastatic and castration-resistant forms. Over the past two decades, the treatment paradigm has evolved from monotherapy with androgen deprivation therapy (ADT) to a multifaceted approach integrating chemotherapy, androgen receptor axis-targeted therapies (ARATs), radiopharmaceuticals, and precision medicine. This review explores the molecular underpinnings of PCa, including genetic and epigenetic alterations such as BRCA1/2, TP53, and PTEN mutations, and their role in disease progression and treatment resistance. We detail the evidence supporting the integration of systemic agents like abiraterone, enzalutamide, and darolutamide into both hormone-sensitive and castration-resistant settings. Furthermore, we highlight the expanding role of radioligand therapies, including radium-223 and Lutetium-177-labeled PSMA-617 (Lu-PSMA-617), as well as the growing impact of PARP inhibitors in genomically selected patients. The emergence of theranostic strategies and next-generation sequencing has paved the way for personalized treatment algorithms, moving toward a truly precision oncology model in PCa. This comprehensive review synthesizes current therapeutic strategies, clinical trial evidence, and future directions aimed at optimizing outcomes and quality of life for patients with advanced prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleStandard of CareNeoplasm MetastasisPrecision MedicineMolecular Targeted Therapy

Stichwörter der Autor:innen

PARP-inhibitorPI3K/AKT/mTOR inhibitorsabiraterone acetatoapalutamidechemotherapy in prostate cancerenzalutamideimmunotherapymetastatic prostate cancerradiopharmaceuticalstarget therapy

Autor:innen und Institutionen

  • Department of Medical Oral and Biotechnological Science, Università degli Studi "G. d'Annunzio" of Chieti, 66100 Chieti, Italy.
  • Department of Anatomy, Surgery and Anesthesiology and Intensive Care, Faculty of Medicine, University Dimitrie Cantemir, 540545 Targu Mures, Romania.
  • Department of Urology, ASSR Santi Paolo e Carlo, University of Milan, 20122 Milan, Italy.
  • Casa di Cura Villa Igea, 60127 Ancona, Italy.

ORCID-Profile: Giulio Litterio, Angelo Orsini, Alessio Digiacomo, Octavian Sabin Tătaru, Carlo Giulioni, Michele Marchioni

Zitieren

APA

Cicchetti, R., Basconi, M., Litterio, G., Orsini, A., Mascitti, M., Digiacomo, A., Salzano, G., Tătaru, O. S., Ferro, M., Giulioni, C., Cafarelli, A., Schips, L., & Marchioni, M. (2025). Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment. International Journal of Molecular Sciences, 26(23), 11665. https://doi.org/10.3390/ijms262311665

Vancouver

Cicchetti R, Basconi M, Litterio G, Orsini A, Mascitti M, Digiacomo A, et al. Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment. International Journal of Molecular Sciences. 2025;26(23):11665. doi:10.3390/ijms262311665

BibTeX
@article{Cicchetti2025,
  author = {Cicchetti, Rossella and Basconi, Martina and Litterio, Giulio and Orsini, Angelo and Mascitti, Marco and Digiacomo, Alessio and Salzano, Gaetano and Tătaru, Octavian Sabin and Ferro, Matteo and Giulioni, Carlo and Cafarelli, Angelo and Schips, Luigi and Marchioni, Michele},
  title = {Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {23},
  pages = {11665},
  doi = {10.3390/ijms262311665}
}
Kostenlos starten →